The European Society of Preventive Medicine Team
Dr Sagner is the Ageing Research at King's (ARK) Clinical Advisor in longevity and preventive medicine. He is a clinician and researcher specialising in sports medicine and preventive medicine, a certified nutritionist and completed his MD at Technical University Munich. He specializes in Sports Medicine, Endocrinology and Preventive Medicine, and had an affiliation with the College of Applied Health Sciences, University of Illinois at Chicago. He was the founding Editor-in-Chief of Progress in Preventive Medicine (Lippincott) and is the Lead Editor of Lifestyle Medicine (Elsevier), Fellow of the Royal Society of Medicine and Fellow of the European Society of Preventative Medicine.
Dr Sagner was the Medical Director and attending physician in the Section for Preventive Medicine and Lifestyle Medicine, University of Hamburg Medical Center. He then co-founded a private clinic group and research institute for cardiology, metabolism, endocrinology, preventive medicine and sports medicine where he looks after elite athletes and executives. As a clinician he has spearheaded interventions in the field of endocrinology and cardiometabolic prevention such as the use of GLP1 agonists in Europe. His focus is on interdisciplinary approaches, looking at the systems of the human body as part of an integrated whole, incorporating biochemical, physiological, and environment interactions and translating these systems biology principles into clinical practice. He works on the convergence of systems biology and consumer-driven healthcare to transform medicine from its current reactive approach to an approach that is predictive, preventive, personalized and participatory (P4). As a public health expert, he has spearheaded several international initiatives in the field of systems biology driven preventive medicine working with governments and NGOs. One of his interests is closing the gap between clinical practice and public health to promote more effective and patient-oriented care and preventive interventions. For that he has collaborated with many NGOs such as the World Heart Federation (WHF), the World Obesity Federation and the World Health Organization (WHO) where he established the ‘cell to community’ approach in prevention.
Dr Sagner is the Founder and Executive Director of the European Society of Preventive Medicine, and partner of the European Innovation Partnership on Active and Healthy Aging. He was a member of the European Union Platform for Action on Diet, Physical Activity and Health, and the UK All-Parliamentary Group for Longevity.
His areas of research are: Advanced Preventive Medicine, Systems Medicine, Metabolism, Noncommunicable Diseases, Longevity, Muscle Physiology and Cardiometabolism and has published numerous articles in this area.
Dr Sagner was the Medical Director and attending physician in the Section for Preventive Medicine and Lifestyle Medicine, University of Hamburg Medical Center. He then co-founded a private clinic group and research institute for cardiology, metabolism, endocrinology, preventive medicine and sports medicine where he looks after elite athletes and executives. As a clinician he has spearheaded interventions in the field of endocrinology and cardiometabolic prevention such as the use of GLP1 agonists in Europe. His focus is on interdisciplinary approaches, looking at the systems of the human body as part of an integrated whole, incorporating biochemical, physiological, and environment interactions and translating these systems biology principles into clinical practice. He works on the convergence of systems biology and consumer-driven healthcare to transform medicine from its current reactive approach to an approach that is predictive, preventive, personalized and participatory (P4). As a public health expert, he has spearheaded several international initiatives in the field of systems biology driven preventive medicine working with governments and NGOs. One of his interests is closing the gap between clinical practice and public health to promote more effective and patient-oriented care and preventive interventions. For that he has collaborated with many NGOs such as the World Heart Federation (WHF), the World Obesity Federation and the World Health Organization (WHO) where he established the ‘cell to community’ approach in prevention.
Dr Sagner is the Founder and Executive Director of the European Society of Preventive Medicine, and partner of the European Innovation Partnership on Active and Healthy Aging. He was a member of the European Union Platform for Action on Diet, Physical Activity and Health, and the UK All-Parliamentary Group for Longevity.
His areas of research are: Advanced Preventive Medicine, Systems Medicine, Metabolism, Noncommunicable Diseases, Longevity, Muscle Physiology and Cardiometabolism and has published numerous articles in this area.
Richard Siow was appointed Secretary General of the European Society for Preventive Medicine in 2023. He is a graduate of King’s College London (BSc, PhD Cardiovascular Physiology) and following postdoctoral research in the Department of Medicine, University of Cambridge, he joined the School of Cardiovascular and Metabolic Medicine & Sciences at King's as a Group Leader in November 2001. He was previously Vice-Dean (International), Faculty of Life Sciences & Medicine (2017-2019). Since 2015 he has been the Director of Ageing Research at King’s (ARK), a cross-university consortium of researchers taking a multidisciplinary approach to better understand the mechanisms of ageing, improving health-span and the social and economic impact of ageing.
He is currently a Professor at Corpus Christi College and affiliated with the Department of Physiology, Anatomy and Genetics, University of Oxford. He has been a Visiting Professor at Oxford since 2023 and was visiting senior academic in the Healthy Longevity Centre at University of Zurich, Switzerland in 2021.
His research team focuses on the role of nutrigenomics and ageing on redox signalling in cardiovascular and cerebrovascular health and disease. His research at King's is primarily based in the British Heart Foundation Centre of Research Excellence and is the Industry Partnerships Lead of the NIHR Health-Tech Research Centre in Brain Health and Centre for Healthy Brain Ageing at Institute of Psychiatry, Psychology and Neuroscience at King's College London.
He has numerous international collaborations including University of Oxford, University of Zurich, Stavanger University Hospital, National University of Singapore, Harvard Medical School, Charite Berlin, Technical University of Dresden and University of Tsukuba, Japan.
Richard championed the Framework Partnership between King’s and Unilever through his research collaborations and one year sabbatical at their global R&D Centres, which led to the establishment of the Unilever Bioscience Innovation Hub at King's.
He is an elected Fellow of the Royal Society of Biology and a Fellow of the European Society for Preventive Medicine and the UK Lead for the International Society on Ageing & Disease. He was previously a Committee Member of the European Society for Microcirculation and Society for Free Radical Research - Europe.
Richard is currently Editor-in-Chief of the Longevity (Taylor & Francis) and previously Specialty Chief Editor (Healthy Longevity Section) of Frontiers in Ageing. He is an Associate Editor of Frontiers in Nutrition and Frontiers in Ageing, and an Editorial Board Member of Antioxidants. He is a member of the International Advisory Board of The Lancet Healthy Longevity and was a member of the Strategic Advisory Board of the All Party Parliamentary Group for Longevity. He has published over 100 peer-reviewed papers and has been awarded over £5m in collaborative research funding.
He is currently a Professor at Corpus Christi College and affiliated with the Department of Physiology, Anatomy and Genetics, University of Oxford. He has been a Visiting Professor at Oxford since 2023 and was visiting senior academic in the Healthy Longevity Centre at University of Zurich, Switzerland in 2021.
His research team focuses on the role of nutrigenomics and ageing on redox signalling in cardiovascular and cerebrovascular health and disease. His research at King's is primarily based in the British Heart Foundation Centre of Research Excellence and is the Industry Partnerships Lead of the NIHR Health-Tech Research Centre in Brain Health and Centre for Healthy Brain Ageing at Institute of Psychiatry, Psychology and Neuroscience at King's College London.
He has numerous international collaborations including University of Oxford, University of Zurich, Stavanger University Hospital, National University of Singapore, Harvard Medical School, Charite Berlin, Technical University of Dresden and University of Tsukuba, Japan.
Richard championed the Framework Partnership between King’s and Unilever through his research collaborations and one year sabbatical at their global R&D Centres, which led to the establishment of the Unilever Bioscience Innovation Hub at King's.
He is an elected Fellow of the Royal Society of Biology and a Fellow of the European Society for Preventive Medicine and the UK Lead for the International Society on Ageing & Disease. He was previously a Committee Member of the European Society for Microcirculation and Society for Free Radical Research - Europe.
Richard is currently Editor-in-Chief of the Longevity (Taylor & Francis) and previously Specialty Chief Editor (Healthy Longevity Section) of Frontiers in Ageing. He is an Associate Editor of Frontiers in Nutrition and Frontiers in Ageing, and an Editorial Board Member of Antioxidants. He is a member of the International Advisory Board of The Lancet Healthy Longevity and was a member of the Strategic Advisory Board of the All Party Parliamentary Group for Longevity. He has published over 100 peer-reviewed papers and has been awarded over £5m in collaborative research funding.
Pekka Puska is a Finnish physician, docent and politician. Puska held the position of Director General of the National Institute for Health and Welfare (THL), Finland in 2009–2013. THL was formed following the merging of National Public Health Institute of Finland (KTL), and the National Research and Development Centre for Welfare and Health (STAKES). Puska headed KTL from 2003 to 2009. Puska is a Member of Parliament (Eduskunta) since 2017 and was previously a Member of Parliament in 1987–1991. Puska is a Docent for University of Helsinki and University of Eastern Finland.
Puska is considered to have had a significant influence on Finnish public health research and practice for several decades. He spearheaded the North Karelia Project (as Director and Principal Investigator) for preventing cardiovascular disease 1972–1977, during which time cardiovascular disease mortality amongst men fell by 80 per cent.[1] Puska worked as a director for NCD prevention and health promotion at the World Health Organization (WHO) Headquarters in 2001–2003.[2] In 2006 he was the Finnish candidate for the Director-General post of WHO. From 2010 to 2013 he was Chancellor of the University of Turku.[3] He also currently holds the position of President of World Heart Federation (WHF) and that of Vice-President of the International Association of Public Health Institutes (IANPHI).
Puska is considered to have had a significant influence on Finnish public health research and practice for several decades. He spearheaded the North Karelia Project (as Director and Principal Investigator) for preventing cardiovascular disease 1972–1977, during which time cardiovascular disease mortality amongst men fell by 80 per cent.[1] Puska worked as a director for NCD prevention and health promotion at the World Health Organization (WHO) Headquarters in 2001–2003.[2] In 2006 he was the Finnish candidate for the Director-General post of WHO. From 2010 to 2013 he was Chancellor of the University of Turku.[3] He also currently holds the position of President of World Heart Federation (WHF) and that of Vice-President of the International Association of Public Health Institutes (IANPHI).
Dr Sanja Brolih is a post-doctoral researcher at the University of Oxford, where she completed her MRes in Oncology and DPhil in Medical Sciences. Her expertise spans haematology, oncology and blood diagnostics. She is currently investigating the therapeutic development and discovery of novel biomarkers, with a particular focus on translating scientific advances into clinical applications, including early disease detection and healthy ageing.
She has established international collaborations across academia, healthcare and the pharmaceutical industry, including research partnerships with Pfizer and AstraZeneca. Her scientific contributions have been recognised through several prestigious awards, including the University of Oxford's Ita Askonas Medal and Prize, and awards from the British and European Society for Haematology.
Beyond her research, Sanja is passionate about fostering connections between scientists, industry leaders and the wider life sciences community. At ESPM, she is responsible for scientific initiatives and fundraising, supporting interdisciplinary partnerships, research innovation and the advancement of preventive medicine.
She has established international collaborations across academia, healthcare and the pharmaceutical industry, including research partnerships with Pfizer and AstraZeneca. Her scientific contributions have been recognised through several prestigious awards, including the University of Oxford's Ita Askonas Medal and Prize, and awards from the British and European Society for Haematology.
Beyond her research, Sanja is passionate about fostering connections between scientists, industry leaders and the wider life sciences community. At ESPM, she is responsible for scientific initiatives and fundraising, supporting interdisciplinary partnerships, research innovation and the advancement of preventive medicine.
Felix Strobl graduated in Neuroscience (MSc) from King's College London, UK and brings a comprehensive and holistic perspective on health, prevention and aftercare to his work with a solid background in emergency medicine as a paramedic. He is currently the Business Development Manager at Ayus Medical Devices, Basel, Switzerland and an advisor to Ageing Research at King's (ARK), King's College London.
Felix Strobl is also a trained tenor with international stage experience. He is the initiator of the Long Covid project MEA (Music, Emotion and Atmung/Breathing) in Switzerland, where he conducted research of the therapeutic potential of music in overcoming health challenges with the help of breathing techniques.
As a dynamic speaker, he shares his insights with a wide range of audiences, including companies, educational institutions and health conferences. In addition to his scientific activities, Felix Strobl also works as a trainer and consultant for various companies. His work is characterised by an interdisciplinary approach that combines scientific knowledge with practical applications to promote holistic health.
Felix Strobl is also a trained tenor with international stage experience. He is the initiator of the Long Covid project MEA (Music, Emotion and Atmung/Breathing) in Switzerland, where he conducted research of the therapeutic potential of music in overcoming health challenges with the help of breathing techniques.
As a dynamic speaker, he shares his insights with a wide range of audiences, including companies, educational institutions and health conferences. In addition to his scientific activities, Felix Strobl also works as a trainer and consultant for various companies. His work is characterised by an interdisciplinary approach that combines scientific knowledge with practical applications to promote holistic health.